Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a challenging complication of many chemotherapeutic regimens. It is conventionally managed with antidepressants, antiepileptics, and adjuvants [1]. Neuromodulation, such as dorsal root ganglion (DRG) stimulation, is emerging as a potential treatment for refractory cases. First-line chemotherapy for multiple myeloma includes multiple CIPN-associated agents; however, the utility of DRG stimulation has not yet been described in this setting.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Neuromodulation: Technology at the Neural Interface
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
